Milestone Pharmaceuticals Inc. announced the appointment of Lisa Giles and Robert Wills to its Board of Directors, effective October 1, 2020. Ms. Giles will serve as a member of the Audit Committee of the Board and Dr. Wills will serve as a member of the Nominating & Corporate Governance Committee of the Board. Ms. Giles brings to the Milestone Board of Directors over 35 years of experience in the pharmaceutical industry, including strategic planning, operations, and business development. She is the founder, managing director and Chief Executive Officer of Giles & Associates Consultancy Inc. From 2013 until 2020, Ms. Giles served as Chief Executive Officer of Optivara Inc. She currently serves on the Board of Directors of GenMark Diagnostics Inc. and the Northwestern Memorial Hospital Foundation. Dr. Wills joins the Board with over 35 years of experience in the pharmaceutical industry, including preclinical and clinical research and development, business development, and strategic partnering. Dr. Wills spent over 25 years in a variety of executive roles at Johnson & Johnson, most recently as Vice President, Alliance Management. Dr. Wills currently serves as Chairman of the Board of Directors of CymaBay Therapeutics Inc. and is on the Board of Directors of Oncternal Therapeutics Inc., Parion Sciences Inc., and Go Therapeutics Inc.